{"ticker": {"uuid": "9fcf8882-3f09-461a-96a7-02a3c85d42fa", "symbol": "ABOS", "name": "Acumen Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNNi1MOVQyckREVWdOOUZQNk1LSFR2VmtXQUlIM1QwUms4UDF4SXdoVEMwUU04M1RSUV91a2s3c3NBZjBBVDdJc1ZWYldhbUctdGZSekNLTjVtR3JTVUJFTTlfbnRibUVtazRJaW9CLS1LNWlnSEV6eU41SHVaWTYxTW92YjFTSFVvcHgyZ1BEcVFYQQ?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-15T16:00:03+00:00", "published_display": "15 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Shows Early Alzheimer\u2019s Disease Insights", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/acumen-pharmaceuticals-shows-early-alzheimer-152302121.html", "source_name": "Exec Edge", "published_at": "2026-07-15T15:23:02+00:00", "published_display": "15 Jul 2026 15:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?", "summary": "Acumen Pharmaceuticals (ABOS) has significantly outperformed the Medical sector and its specific industry (Medical - Biomedical and Genetics) year-to-date, with a 19.9% return compared to the sector's -1.1% and the industry's 1.1% average. The company currently holds a Zacks Rank", "url": "https://sg.finance.yahoo.com/news/medical-stocks-lagging-acumen-pharmaceuticals-134002730.html", "source_name": "Market source", "published_at": "2026-07-15T13:40:00", "published_display": "15 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026", "summary": "Acumen Pharmaceuticals presented new data at AAIC 2026 demonstrating enhanced brain delivery of its anti-A\u03b2O antibodies through its Enhanced Brain Delivery\u2122 (EBD\u2122) program, showing improved brain penetration in non-human primates. The company's EBD candidate ACU401 achieved signi", "url": "https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-conference-aaic-2026/2384927/amp", "source_name": "The Manila Times", "published_at": "2026-07-15T11:14:34", "published_display": "15 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "38 Early Alzheimer's Participants Describe Memory and Social Challenges", "summary": "Acumen Pharmaceuticals presented new data at AAIC\u00ae 2026, highlighting significant advancements in its Enhanced Brain Delivery\u2122 (EBD\u2122) program with bispecific antibodies achieving up to 40-fold higher brain exposure in non-human primates. Simultaneously, insights from 38 early Alz", "url": "https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-tm-ebdtm-n863h5d0j4zk.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:14:34", "published_display": "15 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs", "summary": "Acumen Pharmaceuticals and Unlearn have announced a collaboration to use Unlearn's AI-generated digital twins in Acumen's Alzheimer's disease clinical trials. This initiative aims to enhance data-driven decision-making and potentially expedite the development of new therapies for", "url": "https://www.newspressnow.com/sports/chiefs/acumen-pharmaceuticals-and-unlearn-collaborate-to-explore-analyses-of-alzheimers-disease-clinical-programs/article_48d81fb6-4267-53c4-92cd-01bce9251ab6.html", "source_name": "News-Press NOW", "published_at": "2026-07-10T01:15:48", "published_display": "10 Jul 2026 01:15", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery\u2122 (EBD\u2122) Technology and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026", "summary": "Acumen Pharmaceuticals is set to present three key studies at the Alzheimer's Association International Conference (AAIC\u00ae) 2026 in London. The presentations will cover findings on their Enhanced Brain Delivery (EBD\u2122) technology developed in collaboration with JCR Pharmaceuticals,", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/acumen-pharmaceuticals-to-present-data-on-enhanced-brain-delivery-ebd-technology-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-conference-aaic-2026/2379773", "source_name": "The Manila Times", "published_at": "2026-07-08T11:40:59", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen to show brain-delivery data and patient insights at AAIC 2026", "summary": "Acumen Pharmaceuticals will present three studies at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15, 2026. These presentations will cover data on their Enhanced Brain Delivery (EBD) bispecific antibodies, which utilize transferrin-recep", "url": "https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-to-present-data-on-enhanced-brain-delivery-tm-bw466dppr8l4.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:09:52", "published_display": "07 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Acumen Pharmaceuticals, Inc. \u2013 NASDAQ:ABOS", "summary": "This article provides a brief overview regarding the number of shareholders for Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS). It appears to be a stub or a section focused solely on the \"Number of shareholders\" value, which is not populated in the provided content. The article is p", "url": "https://www.tradingview.com/symbols/NASDAQ-ABOS/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-03T12:40:15", "published_display": "03 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc. commits to advancing targeted therapies for Alzheimer care", "summary": "Acumen Pharmaceuticals, Inc. has reaffirmed its dedication to developing targeted treatments for Alzheimer's disease, emphasizing its support for affected individuals and their families. The company's ongoing research aims to preserve meaningful life moments for patients and care", "url": "https://tradersunion.com/news/companies/show/2531368-acumen-alzheimer-innovation/", "source_name": "Traders Union", "published_at": "2026-07-01T08:40:43", "published_display": "01 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Index", "summary": "Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS) has been added to the Russell 2000 Index, as well as the Russell 2000 Value Benchmark, Russell Small Cap Comp Value Benchmark, Russell 2500, Russell 2500 Value, and Russell 3000 Indices. The company, a clinical-stage biopharmaceutical", "url": "https://www.marketscreener.com/news/acumen-pharmaceuticals-inc-nasdaqgs-abos-added-to-russell-2000-index-ce7f5fdfdc8cff2c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T22:09:35", "published_display": "29 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2500 Index", "summary": "Acumen Pharmaceuticals, Inc. (NasdaqGS:ABOS) has been added to the Russell 2500 Index, as announced on June 28, 2026. This inclusion reflects the company's growing presence in the market and follows its recent addition to several other Russell indices, including the Russell 2000 ", "url": "https://www.marketscreener.com/news/acumen-pharmaceuticals-inc-nasdaqgs-abos-added-to-russell-2500-index-ce7f5fdfd18bf225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:09:18", "published_display": "29 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Value Benchmark", "summary": "Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS) has been added to the Russell 2000 Value Benchmark. The company, a clinical-stage biopharmaceutical firm, focuses on developing treatments for Alzheimer's disease, including its lead immunotherapy drug candidate, sabirnetug (ACU193). ", "url": "https://www.marketscreener.com/news/acumen-pharmaceuticals-inc-nasdaqgs-abos-added-to-russell-2000-value-benchmark-ce7f5fdfd88ffe24", "source_name": "marketscreener.com", "published_at": "2026-06-29T15:40:48", "published_display": "29 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ABOS)", "summary": "This article provides an overview of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) with financial actuals and estimates. It covers the current stock price, historical performance, analyst forecasts, market capitalization, upcoming earnings reports, and other key financial data. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-ABOS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:42:36", "published_display": "25 Jun 2026 23:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABOS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Acumen Pharmaceuticals, Inc. (ABOS) stock, including price targets from analysts, historical performance data, and financial metrics. It highlights that analysts have a maximum estimate of $10.00 and a minimum estimate of $4.00 for the stock's", "url": "https://www.tradingview.com/symbols/NASDAQ-ABOS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:42:36", "published_display": "25 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer\u2019s Disease, Enabled by J-Brain Cargo\u00ae Technology Platform", "summary": "JCR Pharmaceuticals announced that Acumen Pharmaceuticals has exercised its exclusive option to develop, manufacture, and commercialize up to two Alzheimer's disease therapeutic candidates using JCR's J-Brain Cargo\u00ae technology platform. This partnership aims to create a blood-bra", "url": "https://www.biospace.com/press-releases/jcr-pharmaceuticals-announces-that-acumen-pharmaceuticals-has-exercised-its-exclusive-option-to-develop-therapeutic-candidates-for-alzheimers-disease-enabled-by-j-brain-cargo-technology-platform", "source_name": "BioSpace", "published_at": "2026-06-18T06:40:09", "published_display": "18 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Inc (ABOS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Acumen Pharmaceuticals Inc (ABOS) currently holds a weak financial score of 5.54, ranking 347 out of 388", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abos/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:09", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Inc (ABOS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a historical overview of dividends and stock splits for Acumen Pharmaceuticals Inc (ABOS). It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The financial data displayed current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abos/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:14", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals director Porter sells $75,239 in stock", "summary": "Derrell Porter, a director at Acumen Pharmaceuticals, sold $75,239 worth of common stock between June 15 and June 17, 2026, at prices ranging from $2.325 to $2.345 per share. Prior to these sales, Porter acquired shares through the exercise of stock options at $1.07 per share. Fo", "url": "https://m.uk.investing.com/news/insider-trading-news/acumen-pharmaceuticals-director-porter-sells-75239-in-stock-93CH-4734084?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-17T23:40:09", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Inc (ABOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution \u2014 TradingKey", "summary": "This article from TradingKey provides an overview of Acumen Pharmaceuticals Inc (ABOS) with a focus on its market capitalization and current stock price. It highlights that detailed revenue breakdown data by business segments and regions have not yet been disclosed by the company", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abos/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:14", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals (ABOS) director sells 32,300 shares after exercising options", "summary": "Derrell Porter, a director at Acumen Pharmaceuticals (ABOS), exercised options for 19,500 shares and subsequently sold 32,300 shares of common stock between June 15-17, 2026. The exercised options were priced at $1.07 per share, while the sales occurred at weighted average prices", "url": "https://www.stocktitan.net/sec-filings/ABOS/form-4-acumen-pharmaceuticals-inc-insider-trading-activity-9c884b4a7c1a.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:39:14", "published_display": "17 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen exercises option for JCR brain technology", "summary": "Acumen Pharmaceuticals has exercised its exclusive option with JCR Pharmaceuticals to develop and commercialize two Alzheimer\u2019s disease candidates using JCR's J-Brain Cargo platform. This collaboration aims to deliver therapeutic antibodies across the blood-brain barrier for bett", "url": "https://grafa.com/en/news/united-states/acumen-exercises-option-for-jcr-brain-technology", "source_name": "grafa.com", "published_at": "2026-06-17T20:39:14", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Exercises Option on Alzheimer's Program Using JCR's Technology", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/acumen-pharmaceuticals-exercises-option-alzheimer-172220379.html", "source_name": "MT Newswires", "published_at": "2026-06-17T17:22:20+00:00", "published_display": "17 Jun 2026 17:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen bets on JCR\u2019s brain-barrier tech for Alzheimer\u2019s drug candidates", "summary": "Acumen Pharmaceuticals has exercised its exclusive option with JCR Pharmaceuticals to develop, manufacture, and commercialize up to two Alzheimer's disease drug candidates using JCR's J-Brain Cargo\u00ae technology. This strategic partnership, announced in July 2025, aims to create a ", "url": "https://www.stocktitan.net/news/ABOS/jcr-pharmaceuticals-announces-that-acumen-pharmaceuticals-has-6k2ax1e9t44d.html", "source_name": "Stock Titan", "published_at": "2026-06-17T16:39:14", "published_display": "17 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director to sell 13,040 shares (NASDAQ: ABOS) in stock option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOUkdNbTR3TnJVQXI4aWVXcFFFOTdzcjEzY3N4QWdXZDFYWnl5WFgyM3ZQRWF3QXItYTY0N0R5YTVlVDBPLTI0WXVyZU9hT192RklpMGlqRDBpOTM5cGpkSVZuRllXcEJETzAzbk1NRDNhRGFuSzZjTEs3STF3aS01bUdzUS1NZHBEbDhWamx5TG9VLUVEaXRkd2labWpPdnJqZ3BBZzhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen nominates two Alzheimer\u2019s candidates for development By Investing.com", "summary": "Acumen Pharmaceuticals Inc. has nominated two Alzheimer\u2019s drug candidates, ACU301 and ACU401, for development using its amyloid beta oligomer-selective antibody technology combined with JCR Pharmaceuticals' J-Brain Cargo platform for enhanced brain delivery. Preclinical studies s", "url": "https://m.za.investing.com/news/stock-market-news/acumen-nominates-two-alzheimers-candidates-for-development-93CH-4330399?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-17T02:11:47", "published_display": "17 Jun 2026 02:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Nominates 2 Therapies to Treat Alzheimer\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/acumen-nominates-2-therapies-treat-221817738.html", "source_name": "Exec Edge", "published_at": "2026-06-16T22:18:17+00:00", "published_display": "16 Jun 2026 22:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABOS (NASDAQ: ABOS) Form 144 shows proposed sale of 12,800 shares", "summary": "Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has submitted a Form 144 filing indicating a proposed sale of 12,800 shares of restricted common stock. The filing also reports that 6,460 shares were sold on June 15, 2026, for proceeds of $15,148.70, with Morgan Stanley Smith Barney L", "url": "https://www.stocktitan.net/sec-filings/ABOS/144-acumen-pharmaceuticals-inc-sec-filing-aa20d23b1dc5.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:36", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Nominates 2 Drug Candidates to Treat Alzheimer's Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/acumen-pharmaceuticals-nominates-2-drug-120936254.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:09:36+00:00", "published_display": "16 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals nominates two EBD candidates, targets mid-2027 IND with 14-40x brain penetration in NHPs", "summary": "Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) candidates, derived from sabirnetug and ACU234, for development, targeting a mid-2027 IND submission. Preclinical data in NHPs showed 14\u201340x higher brain antibody levels compared to native antibodies, alongsid", "url": "https://www.tradingview.com/news/tradingview:7ee33dce30302:0-acumen-pharmaceuticals-nominates-two-ebd-candidates-targets-mid-2027-ind-with-14-40x-brain-penetration-in-nhps/", "source_name": "TradingView", "published_at": "2026-06-16T12:09:36", "published_display": "16 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen (NASDAQ: ABOS) advances two EBD Alzheimer\u2019s drug candidates", "summary": "Acumen Pharmaceuticals (NASDAQ: ABOS) has nominated two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for Alzheimer's disease, exercising its option to license and develop them in collaboration with JCR Pharmaceuticals. These candidates utilize JCR's J-", "url": "https://www.stocktitan.net/sec-filings/ABOS/8-k-acumen-pharmaceuticals-inc-reports-material-event-a8d64419bb17.html", "source_name": "Stock Titan", "published_at": "2026-06-16T11:40:56", "published_display": "16 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new antibody designs aim for higher brain delivery in Alzheimer\u2019s", "summary": "Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for Alzheimer's disease treatment. These candidates combine Acumen's A\u03b2O-selective antibodies with JCR Pharmaceuticals' J-Brain Cargo\u00ae technology to improve blood-bra", "url": "https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-announces-nomination-of-two-enhanced-brain-rhx7yu51yttm.html", "source_name": "Stock Titan", "published_at": "2026-06-16T11:40:55", "published_display": "16 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Nominates Two Development Candidates in Enhanced Brain Delivery Program for Alzheimer's Disease Treatment", "summary": "Acumen Pharmaceuticals has nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery (EBD) program for Alzheimer's disease treatment, utilizing JCR Pharmaceuticals' J-Brain Cargo\u00ae technology. These candidates aim for improved brain penetration and sa", "url": "https://www.quiverquant.com/news/Acumen+Pharmaceuticals+Nominates+Two+Development+Candidates+in+Enhanced+Brain+Delivery+Program+for+Alzheimer%27s+Disease+Treatment", "source_name": "Quiver Quantitative", "published_at": "2026-06-16T11:40:55", "published_display": "16 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNZDJqclRtVE1FZEZ5ZGkzcThZTzJsREdYeDM1Si1IV1lwTlB1ZVRSbEhLMlBCVl8ya1VCYWpYekQtMEt2Y1F6U3lNa2p3V21BMU0xZ2RiQnVjNnBPc21MM0FPbHFEQUp4RE1mYkxoQnBuX0ZhV09tdlRsV1BpVWdGT3FuQzVtZ2l0amtablcyMy01UUFkUHNWdjNXT01mRldLMnJsQk1ZUWljTWFWWG14RllYWEhyWkdGbWlrMFJPZW5nLXpiUG9Wa2hwOFBCXzBZU0pPLW1ZdWZoWENXUlozZzN2RURDQ25md20tTTNpY3lDdWs?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen\u2019s Late-2026 Sabirnetug Readout Is A Viable Bet (NASDAQ:ABOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPVTREdmRPM2x5QnVUdGVyU3VfajJEYlJWWkJ5U1JoYnJ6OGphNHlBbTl6WEVIVXd5RXF4SUx0TVRtY2lHWlVqcWhXVVBoMm5OalVyanBGT1dueHVMalNqS3hLTmNWWmt5ZnU1Uk1WNXdiUHFhWTdhRmp5Sm9TalhMS2FURWMyQUZOWW1CeHJWS0ZWWTAzclFSY2NBRWxZVHdUQlE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alzheimer\u2019s trial data slated for late 2026 as Acumen holds $128M cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNZXl2UlJ2U0gzWDVBamp5NGV3SEM5OENBOWgzemI5M05LckM0eUlpWXRFdTl4UkwyNFpyTUl0RXhrb1pKZmlQMnYzWnJTdmV2cVNreEwtT2FJRFNMcE9qVmx5Rk5WYWlaOTZOX2ljNDdkeGRITmM4eGM3VHdCV3RRTDN0b3lWNHA5US1vNDNpekE3aEZWWlpFUEZOdDNxUXJpOTFsbWtUSnRfeHdma3BlOEp6QXZYVjh5ZWVzNGthTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Provides Business Update and Financial Results Highlighting Phase 2 Study Progress for Alzheimer\u2019s Treatment and Future Milestones | ABOS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxNUEZzVEk1ak1YMU1YbHlzSGFSWHhtLWxkM0hnc0Y2SlJNbXRFX2FGS3lmR20ySV9MUmpRNU9BU2w4TDFOWDI0SHV6U29vSHZPdmZibVJjdzY4U1YtblNrcWhiczA1M3EyU1lxdEsxU0VqandMYWl4TTJwS21GejRua3V2LW92a1J5NHE2Ml9hOUlVM2YwcGZBNXhYZUlkNEt5VlJ4M0Z3NHdJbXc5UzhZOFZ2cGJYNldVZTY5YTV3Wmw5UXJ1Vks5Sm1FRjFna1BpeXRwNnE1ZEJ6cmNTZWkxc2RFaG5BTDZCelhISXY0ZUpXRGxxTS0xc1ZfZUhtbWc5X1VZdm52SVlySGZrMVF0NHpqU3pmY19xVldVUWllaw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Acumen executives take Bank of America health care stage May 14", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPNVpac1B4YUNpUmFoVjlFamhFdDNkTnU3QjZtSmN0SVkzUTNiWTVGNUpQZVZHcTBIN1F6YkZEdnZWVFdqTHYzUHRxU2VCVnpteTdFMHRNZGlSUHZwei13a1ZBTVhlRmMySDNhZEdjZjdqbnhoNURUYzNvWnc3QUc2U1p3bk15R1B1QWtBclRORnE0VVhYT2lVc21xU19EWUhpcFd1Q1N2VGxnTG5zd1BxZzNRc3pzUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZzI4SEhkWm4xc3g2NnJBdWRiMHBXRGNyOGsxcE5kT2p0ZUVnM1BROVZvbG1LMWpsMy1RckVteGxJcDRmUTlyRXNIQW56cHpwX1VCQ2J1QnhfT1pnTl85NWx1eVZMYldMYnQtS0ZHcEVlcWVLbWRpR3ZzQVc3MmdFbFVtYi11WTF1ck1vNEhOSXdUMnlPQXFHckFpdG91T0Qxaks0?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Acumen Pharmaceuticals (ABOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1UaHVQTld0SVlKQTl0SFlTYTQ0TU9nVzFIbFVNZWpJR19xUjJUa0lpSlRJZzZTOER3akZMU2hlUVN5eTBXVm8tUmh0djdTNkx5a0dmSkxnaEtTTFpMUm5KMElfcDBfaW1oalFUeA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQOVBsclllQXloM0t5cDRRUDBFVE1PWE1aVGJ6WWJtVjY2bXcyTkcwR0hsNEZCMGo0NHl2T1MydEFjbml0U2tyZW8yMmFEY2pfaVBTenZoQTFWa3NQSlRvUVQ0QWhYZjJWQ0pEbzFhVmtCc091YlBvdWRTWWpCMnhaelJRSy15b3E2eHV0b3RETmp4elQtczVHV19IVXhtVUM3M1R5NmZxa25PSWph?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOcWZlc0plZ1VjN1F0OHRuRVV5dm1zdGFWYjc0RlctN2xoTkRKM3NTTzhZelZnYzFmWTg1Rk9MRWVIMUR5bllIWENNZEJlaG5RYnpFWTNnQ3Q3Mk9qV1VVQTJwTU1oM19VZlhfUWVfbGJ2M2NBLXJDTlFQc3RBSExPTF8zNDBHeDdTajFZeHBwMF9pcFZBZzJQeg?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOamJzS3VuT24xbUhuQTJNaGM4UWY2ME5YdTlIZmtCcEI1cXpsYWVhNThJc0ptaHhLcGpZWTVUMXl4ZzJQdk5pQWNDcHMtdE0yVVpIRnBQeVZycjVJWTNCV2RJSWhtSUVET3o1RG1Sc2F6VnlwaE1QWWdnb0djVVh0TUxuakY1OHo5dGc?oc=5", "source_name": "Market source", "published_at": "2025-11-28T08:00:00+00:00", "published_display": "28 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer\u2019s Disease, Enabled by J-Brain Cargo\u00ae Technology Platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxQT0pEZkxiU3RVdGtubnRuM0RVNzZxZTRxaDFIOFVUTGFLbHNSUUF4M2xCQk1vQTdaSmFlY2VwdU81ckdGcmtxUTZhel9NV0IySHV2TFNha1N4RG13eGRjQl9KYllFbWdYWW1kZmFWY2ZEVXpCWm5qQktRMi0wdGd6NFhKM1NZbU95UjEwa2ozOXd6dkFmM1JHT0NiVjFhdWVmRk5tYks4NnJORGh6RklKWm03bjY0eDN6QTNldU85NkNwMzBoYjd4UzFVX0poOHQ2cUVsLVgyOEJZMWc1MzFGWktIZGxmQ2ptUEFFNlV1ZkZ5NFNsVTVmZDFoN2h0TWNDR0gzS2lJeXZOOExoZ3o3cDhRaC1LZVpMU1FhRm00YlRQaS11akpVWG5RTDVtakVFTE43RHVtTlA?oc=5", "source_name": "Business Wire", "published_at": "2025-07-15T07:00:00+00:00", "published_display": "15 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBzdF83QVh5djJRRkIwNmd5MGtyUTR1eGE2NmVYWGpHS3JvR0lPb3JrYU5JZjk2bzRKWnd2bmV2UFN6b29MVGg5UHpHVkRDMm5mN19j?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:31:19+00:00", "published_display": "24 Apr 2025 22:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNNi1MOVQyckREVWdOOUZQNk1LSFR2VmtXQUlIM1QwUms4UDF4SXdoVEMwUU04M1RSUV91a2s3c3NBZjBBVDdJc1ZWYldhbUctdGZSekNLTjVtR3JTVUJFTTlfbnRibUVtazRJaW9CLS1LNWlnSEV6eU41SHVaWTYxTW92YjFTSFVvcHgyZ1BEcVFYQQ?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-15T16:00:03+00:00", "published_display": "15 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Shows Early Alzheimer\u2019s Disease Insights", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/acumen-pharmaceuticals-shows-early-alzheimer-152302121.html", "source_name": "Exec Edge", "published_at": "2026-07-15T15:23:02+00:00", "published_display": "15 Jul 2026 15:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?", "summary": "Acumen Pharmaceuticals (ABOS) has significantly outperformed the Medical sector and its specific industry (Medical - Biomedical and Genetics) year-to-date, with a 19.9% return compared to the sector's -1.1% and the industry's 1.1% average. The company currently holds a Zacks Rank", "url": "https://sg.finance.yahoo.com/news/medical-stocks-lagging-acumen-pharmaceuticals-134002730.html", "source_name": "Market source", "published_at": "2026-07-15T13:40:00", "published_display": "15 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Highlights Enhanced Brain Delivery\u2122 (EBD\u2122) Program Data and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026", "summary": "Acumen Pharmaceuticals presented new data at AAIC 2026 demonstrating enhanced brain delivery of its anti-A\u03b2O antibodies through its Enhanced Brain Delivery\u2122 (EBD\u2122) program, showing improved brain penetration in non-human primates. The company's EBD candidate ACU401 achieved signi", "url": "https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-conference-aaic-2026/2384927/amp", "source_name": "The Manila Times", "published_at": "2026-07-15T11:14:34", "published_display": "15 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "38 Early Alzheimer's Participants Describe Memory and Social Challenges", "summary": "Acumen Pharmaceuticals presented new data at AAIC\u00ae 2026, highlighting significant advancements in its Enhanced Brain Delivery\u2122 (EBD\u2122) program with bispecific antibodies achieving up to 40-fold higher brain exposure in non-human primates. Simultaneously, insights from 38 early Alz", "url": "https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-tm-ebdtm-n863h5d0j4zk.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:14:34", "published_display": "15 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs", "summary": "Acumen Pharmaceuticals and Unlearn have announced a collaboration to use Unlearn's AI-generated digital twins in Acumen's Alzheimer's disease clinical trials. This initiative aims to enhance data-driven decision-making and potentially expedite the development of new therapies for", "url": "https://www.newspressnow.com/sports/chiefs/acumen-pharmaceuticals-and-unlearn-collaborate-to-explore-analyses-of-alzheimers-disease-clinical-programs/article_48d81fb6-4267-53c4-92cd-01bce9251ab6.html", "source_name": "News-Press NOW", "published_at": "2026-07-10T01:15:48", "published_display": "10 Jul 2026 01:15", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery\u2122 (EBD\u2122) Technology and Early Alzheimer\u2019s Disease Insights at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2026", "summary": "Acumen Pharmaceuticals is set to present three key studies at the Alzheimer's Association International Conference (AAIC\u00ae) 2026 in London. The presentations will cover findings on their Enhanced Brain Delivery (EBD\u2122) technology developed in collaboration with JCR Pharmaceuticals,", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/acumen-pharmaceuticals-to-present-data-on-enhanced-brain-delivery-ebd-technology-and-early-alzheimers-disease-insights-at-the-alzheimers-association-international-conference-aaic-2026/2379773", "source_name": "The Manila Times", "published_at": "2026-07-08T11:40:59", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen to show brain-delivery data and patient insights at AAIC 2026", "summary": "Acumen Pharmaceuticals will present three studies at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15, 2026. These presentations will cover data on their Enhanced Brain Delivery (EBD) bispecific antibodies, which utilize transferrin-recep", "url": "https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-to-present-data-on-enhanced-brain-delivery-tm-bw466dppr8l4.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:09:52", "published_display": "07 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Acumen Pharmaceuticals, Inc. \u2013 NASDAQ:ABOS", "summary": "This article provides a brief overview regarding the number of shareholders for Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS). It appears to be a stub or a section focused solely on the \"Number of shareholders\" value, which is not populated in the provided content. The article is p", "url": "https://www.tradingview.com/symbols/NASDAQ-ABOS/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-03T12:40:15", "published_display": "03 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc. commits to advancing targeted therapies for Alzheimer care", "summary": "Acumen Pharmaceuticals, Inc. has reaffirmed its dedication to developing targeted treatments for Alzheimer's disease, emphasizing its support for affected individuals and their families. The company's ongoing research aims to preserve meaningful life moments for patients and care", "url": "https://tradersunion.com/news/companies/show/2531368-acumen-alzheimer-innovation/", "source_name": "Traders Union", "published_at": "2026-07-01T08:40:43", "published_display": "01 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Index", "summary": "Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS) has been added to the Russell 2000 Index, as well as the Russell 2000 Value Benchmark, Russell Small Cap Comp Value Benchmark, Russell 2500, Russell 2500 Value, and Russell 3000 Indices. The company, a clinical-stage biopharmaceutical", "url": "https://www.marketscreener.com/news/acumen-pharmaceuticals-inc-nasdaqgs-abos-added-to-russell-2000-index-ce7f5fdfdc8cff2c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T22:09:35", "published_display": "29 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2500 Index", "summary": "Acumen Pharmaceuticals, Inc. (NasdaqGS:ABOS) has been added to the Russell 2500 Index, as announced on June 28, 2026. This inclusion reflects the company's growing presence in the market and follows its recent addition to several other Russell indices, including the Russell 2000 ", "url": "https://www.marketscreener.com/news/acumen-pharmaceuticals-inc-nasdaqgs-abos-added-to-russell-2500-index-ce7f5fdfd18bf225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:09:18", "published_display": "29 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Value Benchmark", "summary": "Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS) has been added to the Russell 2000 Value Benchmark. The company, a clinical-stage biopharmaceutical firm, focuses on developing treatments for Alzheimer's disease, including its lead immunotherapy drug candidate, sabirnetug (ACU193). ", "url": "https://www.marketscreener.com/news/acumen-pharmaceuticals-inc-nasdaqgs-abos-added-to-russell-2000-value-benchmark-ce7f5fdfd88ffe24", "source_name": "marketscreener.com", "published_at": "2026-06-29T15:40:48", "published_display": "29 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ABOS)", "summary": "This article provides an overview of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) with financial actuals and estimates. It covers the current stock price, historical performance, analyst forecasts, market capitalization, upcoming earnings reports, and other key financial data. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-ABOS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:42:36", "published_display": "25 Jun 2026 23:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABOS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Acumen Pharmaceuticals, Inc. (ABOS) stock, including price targets from analysts, historical performance data, and financial metrics. It highlights that analysts have a maximum estimate of $10.00 and a minimum estimate of $4.00 for the stock's", "url": "https://www.tradingview.com/symbols/NASDAQ-ABOS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:42:36", "published_display": "25 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer\u2019s Disease, Enabled by J-Brain Cargo\u00ae Technology Platform", "summary": "JCR Pharmaceuticals announced that Acumen Pharmaceuticals has exercised its exclusive option to develop, manufacture, and commercialize up to two Alzheimer's disease therapeutic candidates using JCR's J-Brain Cargo\u00ae technology platform. This partnership aims to create a blood-bra", "url": "https://www.biospace.com/press-releases/jcr-pharmaceuticals-announces-that-acumen-pharmaceuticals-has-exercised-its-exclusive-option-to-develop-therapeutic-candidates-for-alzheimers-disease-enabled-by-j-brain-cargo-technology-platform", "source_name": "BioSpace", "published_at": "2026-06-18T06:40:09", "published_display": "18 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Inc (ABOS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Acumen Pharmaceuticals Inc (ABOS) currently holds a weak financial score of 5.54, ranking 347 out of 388", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abos/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:09", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Inc (ABOS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a historical overview of dividends and stock splits for Acumen Pharmaceuticals Inc (ABOS). It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The financial data displayed current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abos/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:14", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals director Porter sells $75,239 in stock", "summary": "Derrell Porter, a director at Acumen Pharmaceuticals, sold $75,239 worth of common stock between June 15 and June 17, 2026, at prices ranging from $2.325 to $2.345 per share. Prior to these sales, Porter acquired shares through the exercise of stock options at $1.07 per share. Fo", "url": "https://m.uk.investing.com/news/insider-trading-news/acumen-pharmaceuticals-director-porter-sells-75239-in-stock-93CH-4734084?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-17T23:40:09", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Inc (ABOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution \u2014 TradingKey", "summary": "This article from TradingKey provides an overview of Acumen Pharmaceuticals Inc (ABOS) with a focus on its market capitalization and current stock price. It highlights that detailed revenue breakdown data by business segments and regions have not yet been disclosed by the company", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abos/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:14", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals (ABOS) director sells 32,300 shares after exercising options", "summary": "Derrell Porter, a director at Acumen Pharmaceuticals (ABOS), exercised options for 19,500 shares and subsequently sold 32,300 shares of common stock between June 15-17, 2026. The exercised options were priced at $1.07 per share, while the sales occurred at weighted average prices", "url": "https://www.stocktitan.net/sec-filings/ABOS/form-4-acumen-pharmaceuticals-inc-insider-trading-activity-9c884b4a7c1a.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:39:14", "published_display": "17 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen exercises option for JCR brain technology", "summary": "Acumen Pharmaceuticals has exercised its exclusive option with JCR Pharmaceuticals to develop and commercialize two Alzheimer\u2019s disease candidates using JCR's J-Brain Cargo platform. This collaboration aims to deliver therapeutic antibodies across the blood-brain barrier for bett", "url": "https://grafa.com/en/news/united-states/acumen-exercises-option-for-jcr-brain-technology", "source_name": "grafa.com", "published_at": "2026-06-17T20:39:14", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Exercises Option on Alzheimer's Program Using JCR's Technology", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/acumen-pharmaceuticals-exercises-option-alzheimer-172220379.html", "source_name": "MT Newswires", "published_at": "2026-06-17T17:22:20+00:00", "published_display": "17 Jun 2026 17:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen bets on JCR\u2019s brain-barrier tech for Alzheimer\u2019s drug candidates", "summary": "Acumen Pharmaceuticals has exercised its exclusive option with JCR Pharmaceuticals to develop, manufacture, and commercialize up to two Alzheimer's disease drug candidates using JCR's J-Brain Cargo\u00ae technology. This strategic partnership, announced in July 2025, aims to create a ", "url": "https://www.stocktitan.net/news/ABOS/jcr-pharmaceuticals-announces-that-acumen-pharmaceuticals-has-6k2ax1e9t44d.html", "source_name": "Stock Titan", "published_at": "2026-06-17T16:39:14", "published_display": "17 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director to sell 13,040 shares (NASDAQ: ABOS) in stock option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOUkdNbTR3TnJVQXI4aWVXcFFFOTdzcjEzY3N4QWdXZDFYWnl5WFgyM3ZQRWF3QXItYTY0N0R5YTVlVDBPLTI0WXVyZU9hT192RklpMGlqRDBpOTM5cGpkSVZuRllXcEJETzAzbk1NRDNhRGFuSzZjTEs3STF3aS01bUdzUS1NZHBEbDhWamx5TG9VLUVEaXRkd2labWpPdnJqZ3BBZzhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen nominates two Alzheimer\u2019s candidates for development By Investing.com", "summary": "Acumen Pharmaceuticals Inc. has nominated two Alzheimer\u2019s drug candidates, ACU301 and ACU401, for development using its amyloid beta oligomer-selective antibody technology combined with JCR Pharmaceuticals' J-Brain Cargo platform for enhanced brain delivery. Preclinical studies s", "url": "https://m.za.investing.com/news/stock-market-news/acumen-nominates-two-alzheimers-candidates-for-development-93CH-4330399?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-17T02:11:47", "published_display": "17 Jun 2026 02:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Nominates 2 Therapies to Treat Alzheimer\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/acumen-nominates-2-therapies-treat-221817738.html", "source_name": "Exec Edge", "published_at": "2026-06-16T22:18:17+00:00", "published_display": "16 Jun 2026 22:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABOS (NASDAQ: ABOS) Form 144 shows proposed sale of 12,800 shares", "summary": "Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has submitted a Form 144 filing indicating a proposed sale of 12,800 shares of restricted common stock. The filing also reports that 6,460 shares were sold on June 15, 2026, for proceeds of $15,148.70, with Morgan Stanley Smith Barney L", "url": "https://www.stocktitan.net/sec-filings/ABOS/144-acumen-pharmaceuticals-inc-sec-filing-aa20d23b1dc5.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:36", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Nominates 2 Drug Candidates to Treat Alzheimer's Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/acumen-pharmaceuticals-nominates-2-drug-120936254.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:09:36+00:00", "published_display": "16 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals nominates two EBD candidates, targets mid-2027 IND with 14-40x brain penetration in NHPs", "summary": "Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) candidates, derived from sabirnetug and ACU234, for development, targeting a mid-2027 IND submission. Preclinical data in NHPs showed 14\u201340x higher brain antibody levels compared to native antibodies, alongsid", "url": "https://www.tradingview.com/news/tradingview:7ee33dce30302:0-acumen-pharmaceuticals-nominates-two-ebd-candidates-targets-mid-2027-ind-with-14-40x-brain-penetration-in-nhps/", "source_name": "TradingView", "published_at": "2026-06-16T12:09:36", "published_display": "16 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen (NASDAQ: ABOS) advances two EBD Alzheimer\u2019s drug candidates", "summary": "Acumen Pharmaceuticals (NASDAQ: ABOS) has nominated two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for Alzheimer's disease, exercising its option to license and develop them in collaboration with JCR Pharmaceuticals. These candidates utilize JCR's J-", "url": "https://www.stocktitan.net/sec-filings/ABOS/8-k-acumen-pharmaceuticals-inc-reports-material-event-a8d64419bb17.html", "source_name": "Stock Titan", "published_at": "2026-06-16T11:40:56", "published_display": "16 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new antibody designs aim for higher brain delivery in Alzheimer\u2019s", "summary": "Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for Alzheimer's disease treatment. These candidates combine Acumen's A\u03b2O-selective antibodies with JCR Pharmaceuticals' J-Brain Cargo\u00ae technology to improve blood-bra", "url": "https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-announces-nomination-of-two-enhanced-brain-rhx7yu51yttm.html", "source_name": "Stock Titan", "published_at": "2026-06-16T11:40:55", "published_display": "16 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Nominates Two Development Candidates in Enhanced Brain Delivery Program for Alzheimer's Disease Treatment", "summary": "Acumen Pharmaceuticals has nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery (EBD) program for Alzheimer's disease treatment, utilizing JCR Pharmaceuticals' J-Brain Cargo\u00ae technology. These candidates aim for improved brain penetration and sa", "url": "https://www.quiverquant.com/news/Acumen+Pharmaceuticals+Nominates+Two+Development+Candidates+in+Enhanced+Brain+Delivery+Program+for+Alzheimer%27s+Disease+Treatment", "source_name": "Quiver Quantitative", "published_at": "2026-06-16T11:40:55", "published_display": "16 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNZDJqclRtVE1FZEZ5ZGkzcThZTzJsREdYeDM1Si1IV1lwTlB1ZVRSbEhLMlBCVl8ya1VCYWpYekQtMEt2Y1F6U3lNa2p3V21BMU0xZ2RiQnVjNnBPc21MM0FPbHFEQUp4RE1mYkxoQnBuX0ZhV09tdlRsV1BpVWdGT3FuQzVtZ2l0amtablcyMy01UUFkUHNWdjNXT01mRldLMnJsQk1ZUWljTWFWWG14RllYWEhyWkdGbWlrMFJPZW5nLXpiUG9Wa2hwOFBCXzBZU0pPLW1ZdWZoWENXUlozZzN2RURDQ25md20tTTNpY3lDdWs?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen\u2019s Late-2026 Sabirnetug Readout Is A Viable Bet (NASDAQ:ABOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPVTREdmRPM2x5QnVUdGVyU3VfajJEYlJWWkJ5U1JoYnJ6OGphNHlBbTl6WEVIVXd5RXF4SUx0TVRtY2lHWlVqcWhXVVBoMm5OalVyanBGT1dueHVMalNqS3hLTmNWWmt5ZnU1Uk1WNXdiUHFhWTdhRmp5Sm9TalhMS2FURWMyQUZOWW1CeHJWS0ZWWTAzclFSY2NBRWxZVHdUQlE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alzheimer\u2019s trial data slated for late 2026 as Acumen holds $128M cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNZXl2UlJ2U0gzWDVBamp5NGV3SEM5OENBOWgzemI5M05LckM0eUlpWXRFdTl4UkwyNFpyTUl0RXhrb1pKZmlQMnYzWnJTdmV2cVNreEwtT2FJRFNMcE9qVmx5Rk5WYWlaOTZOX2ljNDdkeGRITmM4eGM3VHdCV3RRTDN0b3lWNHA5US1vNDNpekE3aEZWWlpFUEZOdDNxUXJpOTFsbWtUSnRfeHdma3BlOEp6QXZYVjh5ZWVzNGthTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals Provides Business Update and Financial Results Highlighting Phase 2 Study Progress for Alzheimer\u2019s Treatment and Future Milestones | ABOS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxNUEZzVEk1ak1YMU1YbHlzSGFSWHhtLWxkM0hnc0Y2SlJNbXRFX2FGS3lmR20ySV9MUmpRNU9BU2w4TDFOWDI0SHV6U29vSHZPdmZibVJjdzY4U1YtblNrcWhiczA1M3EyU1lxdEsxU0VqandMYWl4TTJwS21GejRua3V2LW92a1J5NHE2Ml9hOUlVM2YwcGZBNXhYZUlkNEt5VlJ4M0Z3NHdJbXc5UzhZOFZ2cGJYNldVZTY5YTV3Wmw5UXJ1Vks5Sm1FRjFna1BpeXRwNnE1ZEJ6cmNTZWkxc2RFaG5BTDZCelhISXY0ZUpXRGxxTS0xc1ZfZUhtbWc5X1VZdm52SVlySGZrMVF0NHpqU3pmY19xVldVUWllaw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen executives take Bank of America health care stage May 14", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPNVpac1B4YUNpUmFoVjlFamhFdDNkTnU3QjZtSmN0SVkzUTNiWTVGNUpQZVZHcTBIN1F6YkZEdnZWVFdqTHYzUHRxU2VCVnpteTdFMHRNZGlSUHZwei13a1ZBTVhlRmMySDNhZEdjZjdqbnhoNURUYzNvWnc3QUc2U1p3bk15R1B1QWtBclRORnE0VVhYT2lVc21xU19EWUhpcFd1Q1N2VGxnTG5zd1BxZzNRc3pzUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZzI4SEhkWm4xc3g2NnJBdWRiMHBXRGNyOGsxcE5kT2p0ZUVnM1BROVZvbG1LMWpsMy1RckVteGxJcDRmUTlyRXNIQW56cHpwX1VCQ2J1QnhfT1pnTl85NWx1eVZMYldMYnQtS0ZHcEVlcWVLbWRpR3ZzQVc3MmdFbFVtYi11WTF1ck1vNEhOSXdUMnlPQXFHckFpdG91T0Qxaks0?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Acumen Pharmaceuticals (ABOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1UaHVQTld0SVlKQTl0SFlTYTQ0TU9nVzFIbFVNZWpJR19xUjJUa0lpSlRJZzZTOER3akZMU2hlUVN5eTBXVm8tUmh0djdTNkx5a0dmSkxnaEtTTFpMUm5KMElfcDBfaW1oalFUeA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQOVBsclllQXloM0t5cDRRUDBFVE1PWE1aVGJ6WWJtVjY2bXcyTkcwR0hsNEZCMGo0NHl2T1MydEFjbml0U2tyZW8yMmFEY2pfaVBTenZoQTFWa3NQSlRvUVQ0QWhYZjJWQ0pEbzFhVmtCc091YlBvdWRTWWpCMnhaelJRSy15b3E2eHV0b3RETmp4elQtczVHV19IVXhtVUM3M1R5NmZxa25PSWph?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOcWZlc0plZ1VjN1F0OHRuRVV5dm1zdGFWYjc0RlctN2xoTkRKM3NTTzhZelZnYzFmWTg1Rk9MRWVIMUR5bllIWENNZEJlaG5RYnpFWTNnQ3Q3Mk9qV1VVQTJwTU1oM19VZlhfUWVfbGJ2M2NBLXJDTlFQc3RBSExPTF8zNDBHeDdTajFZeHBwMF9pcFZBZzJQeg?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOamJzS3VuT24xbUhuQTJNaGM4UWY2ME5YdTlIZmtCcEI1cXpsYWVhNThJc0ptaHhLcGpZWTVUMXl4ZzJQdk5pQWNDcHMtdE0yVVpIRnBQeVZycjVJWTNCV2RJSWhtSUVET3o1RG1Sc2F6VnlwaE1QWWdnb0djVVh0TUxuakY1OHo5dGc?oc=5", "source_name": "Market source", "published_at": "2025-11-28T08:00:00+00:00", "published_display": "28 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer\u2019s Disease, Enabled by J-Brain Cargo\u00ae Technology Platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxQT0pEZkxiU3RVdGtubnRuM0RVNzZxZTRxaDFIOFVUTGFLbHNSUUF4M2xCQk1vQTdaSmFlY2VwdU81ckdGcmtxUTZhel9NV0IySHV2TFNha1N4RG13eGRjQl9KYllFbWdYWW1kZmFWY2ZEVXpCWm5qQktRMi0wdGd6NFhKM1NZbU95UjEwa2ozOXd6dkFmM1JHT0NiVjFhdWVmRk5tYks4NnJORGh6RklKWm03bjY0eDN6QTNldU85NkNwMzBoYjd4UzFVX0poOHQ2cUVsLVgyOEJZMWc1MzFGWktIZGxmQ2ptUEFFNlV1ZkZ5NFNsVTVmZDFoN2h0TWNDR0gzS2lJeXZOOExoZ3o3cDhRaC1LZVpMU1FhRm00YlRQaS11akpVWG5RTDVtakVFTE43RHVtTlA?oc=5", "source_name": "Business Wire", "published_at": "2025-07-15T07:00:00+00:00", "published_display": "15 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBzdF83QVh5djJRRkIwNmd5MGtyUTR1eGE2NmVYWGpHS3JvR0lPb3JrYU5JZjk2bzRKWnd2bmV2UFN6b29MVGg5UHpHVkRDMm5mN19j?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:31:19+00:00", "published_display": "24 Apr 2025 22:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 53, "sentiment_summary": {"positive": 22, "negative": 4, "neutral": 27, "score": 60, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 20.5, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 2.63, "latest_week": "2026-07-10", "one_week_move": -4.0, "four_week_move": 11.0, "twelve_week_move": -6.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.385769, "market_dynamics_buy_signal": false, "relative_strength": 6.286781, "fair_value_gap": 0.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.6859, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.0% over one week, +11.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 72, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 5}, {"label": "TradingKey", "count": 3}, {"label": "Exec Edge", "count": 2}, {"label": "The Manila Times", "count": 2}, {"label": "www.marketscreener.com", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.0% over one week, +11.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy"}], "updated_at": "2026-07-16T02:46:59.763139+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}